Drug Pipeline

M9140 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
1
Phase 3
2
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-29 NCT06710132
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE…		 overall status: "Recruiting" → "Active Not Recruiting"
Active Studies by Phase
Phase 3
1
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07549412 A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to… Metastatic Colorectal Cancer Recruiting
Phase 1/2
NCT06710132 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE… Solid Tumors Active, Not Recruiting
Phase 1
NCT05464030 Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) Colorectal Cancer Recruiting
NCT06806046 Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors Solid Tumors Active, Not Recruiting
Sponsors Running M9140 Trials
EMD Serono Research & Development Institute, Inc. (3) Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)
Disease Areas
Colorectal Cancer (3) Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1) Pancreatic Cancer (1) Gastric Cancer (1)
Get alerts when M9140 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free